An evaluation of the cardiotoxicity of imatinib mesylate

Leukemia Research

Volumn 32, Issue 12, 2008, Pages 1809-1814

  Ribeiro, Antonio Luiz ^a   Marcolino, Milena Soriano ^a   Bittencourt, Henrique N S ^a   Barbosa, Márcia M ^b   Nunes, Maria do Carmo P ^a   Xavier, Vitor Fonseca ^a   Clementino, Nelma C D ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b Hospital Geral Socor   (Brazil)

Author keywords

BNP; Cardiotoxicity; Chronic myeloid leukaemia; Imatinib; Ventricular function

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; IMATINIB;

ADULT; AGED; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; DRUG EFFECT; ECHOCARDIOGRAPHY; FEMALE; HEART FUNCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELOPROLIFERATIVE DISORDER; PERIPHERAL EDEMA; PRIORITY JOURNAL;

AGED; ANTINEOPLASTIC AGENTS; ATRIAL FIBRILLATION; ATRIAL FUNCTION, LEFT; ATRIAL FUNCTION, RIGHT; BLOOD PRESSURE; CARDIOTOXINS; ELECTROCARDIOGRAPHY; HEART RATE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; PIPERAZINES; PYRIMIDINES;

EID: 51649102751     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.03.020     Document Type: Article

References (27)

1. Hehlmann R., Hochhaus A., and Baccarani M. Chronic myeloid leukaemia. Lancet 370 9584 (2007) 342-350
2. Siddiqui M.A., and Scott L.J. Imatinib: a review of its use in the management of gastrointestinal stromal tumours. Drugs 67 5 (2007) 805-820
3. Kerkela R., Grazette L., Yacobi R., Iliescu C., Patten R., Beahm C., et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12 8 (2006) 908-916
4. Schellings M.W., Lowenberg B., and Pinto Y.M. Another look at imatinib mesylate. N Engl J Med 356 11 (2007) 1183
5. Gleevec may be heart toxic. Health News 2007; 13(1):2.
6. Warning is issued on drug for leukemia. The New York Times; July 24; 2007.
7. Druker B.J., Guilhot F., O'brien S.G., Gathmann I., Kantarjian H., Gattermann N., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355 23 (2006) 2408-2417
8. Kantarjian H.M., Talpaz M., O'brien S., Jones D., Giles F., Garcia-Manero G., et al. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood 108 6 (2006) 1835-1840
9. O'brien S.G., Guilhot F., Larson R.A., Gathmann I., Baccarani M., Cervantes F., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348 11 (2003) 994-1004
10. Rosti G., Martinelli G., and Baccarani M. In reply to Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 13 1 (2007) 15-16
11. Atallah E., Kantarjian H., and Cortes J. In reply to Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 13 1 (2007) 14-16
12. Hatfield A., Owen S., and Pilot P.R. In reply to Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 13 1 (2007) 13-16
13. Gambacorti-Passerini C., Tornaghi L., Franceschino A., Piazza R., Corneo G., and Pogliani E. In reply to Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 13 1 (2007) 13-14
14. Atallah E., Durand J.B., Kantarjian H., and Cortes J. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 110 4 (2007) 1233-1237
15. Verweij J., Casali P.G., Kotasek D., Le Cesne A., Reichard P., Judson I.R., et al. Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005. Eur J Cancer 43 6 (2007) 974-978
16. Perik P.J., Rikhof B., de Jong F.A., Verweij J., Gietema J.A., and van der Graaf W.T. Results of plasma N-terminal pro B-type natriuretic peptide and cardiac troponin monitoring in GIST patients do not support the existence of imatinib-induced cardiotoxicity. Ann Oncol (2007)
17. Force T. In reply to Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 13 1 (2007) 15-16
18. Force T., Krause D.S., and Van Etten R.A. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 7 5 (2007) 332-344
19. Jaffe E., Harris N.L., Stein H., and Vardiman J.W. Pathology and genetics: tumours of haematopoietic and lymphoid tissues (World Health Organization Classification of Tumours) (2001), Intl Agency for Research on Cancer, Lyon
20. Bayes De Luna A. Clinical electrocardiography: a textbook. second ed. (1998), Futura Publishing Company, Armonk
21. Henry W.L., DeMaria A., Gramiak R., King D.L., Kisslo J.A., Popp R.L., et al. Report of the American Society of Echocardiography Committee on nomenclature and standards in two-dimensional echocardiography. Circulation 62 2 (1980) 212-217
22. Garcia M.J., Thomas J.D., and Klein A.L. New Doppler echocardiographic applications for the study of diastolic function. J. Am. Coll. Cardiol. 32 4 (1998) 865-875
23. Nagueh S.F., Middleton K.J., Kopelen H.A., Zoghbi W.A., and Quinones M.A. Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol 30 6 (1997) 1527-1533
24. Dao Q., Krishnaswamy P., Kazanegra R., Harrison A., Amirnovin R., Lenert L., et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol 37 2 (2001) 379-385
25. Dupont W.D., and Plummer W.D. Power and sample size calculations: a review and computer program. Control Clin Trials 11 2 (1990) 116-128
26. Park Y.H., Park H.J., Kim B.S., Ha E., Jung K.H., Yoon S.H., et al. BNP as a marker of the heart failure in the treatment of imatinib mesylate. Cancer Lett 243 1 (2006) 16-22
27. Dokainish H., Zoghbi W.A., Lakkis N.M., Al Bakshy F., Dhir M., Quinones M.A., et al. Optimal noninvasive assessment of left ventricular filling pressures: a comparison of tissue Doppler echocardiography and B-type natriuretic peptide in patients with pulmonary artery catheters. Circulation 109 20 (2004) 2432-2439